Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTX 224

Next Previous
Search
Drug Profile

RTX 224

Alternative Names: RTX-224

Latest Information Update: 11 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rubius Therapeutics
  • Developer Rubius Therapeutics [CEASED]
  • Class Antineoplastics; Cell therapies; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies
  • Mechanism of Action Cell replacements; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Dec 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Parenteral) (Rubius Therapeutics website, December 2022)
  • 13 Sep 2022 Rubius Therapeutics discontinues a phase-I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) to restructure the organization to support advancing drug candidates (NCT05219578)
  • 13 Jan 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top